Greveling Holding BV

TILDREN

Composition
Each bottle contains:

Tiludronic acid (as disodium salt)	50 mg

Characteristics
Tiludronic acid, a bisphosphonate, inhibits bone resorption in horses. Tildren regulates bone tissue remodelling in those cases where too much bone resorption (i.e. elevated activity of osteoclasts) occurs. It has an anti-inflammatory effect on arthritis, by inhibiting the secretion of cartilage resorbing enzymes.

Indications
Aid in the treatment of lameness associated with osteolytic processes, in spavin and podotrochleosis existing less than 6 months.

Dosage and administration
Use Tildren only after a good diagnosis using full orthopaedic examination with local anaesthesia and a suitable diagnostic imaging technique.
0,1 mg Tiludronic acid / kg bodyweight (1ml solution / 50 kg) per day during 10 days.
Administer slowly I.V. inject alternating left and right during the consecutive days.
Inject the solvent into the bottle containing the powder and carefully mix these 2 components.

Adverse Reactions
Slight muscle tremors and sweating, colic and a local reaction at the site of injection may occur. These reactions usually occur within a few hours after injection, are transient and need no further treatment. Excitation, hypertonia of tail, excess of saliva and tiredness are possible adverse reactions. Make sure that the horse can lie down without restrictions.

Precautions
Special precautions for use in animals
The clinical effect of the veterinary medicinal product depends on the presence of osteolytic processes that cause pain and thus lameness. The veterinary medicinal product should only be used after a good diagnostics, consisting of a full orthopaedic examination with local anaesthesia and suitable imaging technique, to be used. This is to determine the cause of the pain and the nature of the pain to identify bone lesions.
It is recommended, in connection with the occurrence of possible side effects, that an experienced horse keeper keeps the horse under observation for the first four hours after the injection.
The veterinary medicinal product should be used with more caution in hypocalcemic horses. For these animals it is recommended to reduce the speed of injection.
As the risk of occurrence of side effects may be greater, these horses should be kept in a safe place after treatment and should be subject to special surveillance.
Because of the slightly hypo calcaemic effect, the veterinary medicinal product should be treated with caution administered to horses with functional heart disease.
In these cases it is also recommended to reduce the speed of injection.
When using the veterinary medicinal product, sufficient drinking water must be available. In case of uncertainty about the kidney function, the kidney parameters should be assessed before the veterinary medicinal product is administered. Water consumption and urine excretion should be monitored after administration.

Contraindications
Do not use in horses under 3 years of age. Do not use in horses with impaired kidney function. Do not use in horses producing milk for human consumption.

Withholding period
The Netherlands: 0 days

Warnings
Do not mix the reconstituted solution with two-valent ions, such as Ca^{2+} and Mg^{2+}.
The use during gestation and lactation has been examined insufficiently. Use in carrying or lactating mares is not recommended.
It is recommended to lower the speed of injection in hypocalcemic horses or horses with functional heart disorders.

Storage
Store at 15 – 25°C.
Keep out of reach and sight of children.

Presentation
10 bottles of 50 g powder each.
10 bottles of 10ml solvent each.

Registration (International)
REG NL 10079 UDD